antitumor pathway involving galectin 9, pd-1 and tim-3
Published 2 years ago • 327 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:54
two main pathways involved in immunotherapy pd 1 and ctla4
-
6:31
what are checkpoint inhibitors?
-
4:51
t lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9
-
33:01
head and neck cancer and immunotherapy with dr. trisha wise-draper
-
0:59
dr. galsky on progression on immunotherapy in bladder cancer
-
3:23
immune checkpoints: targeting tigit
-
3:40
discovering the pd-1 checkpoint: winners of the 2014 william b. coley award for tumor immunology
-
2:02
dr. nambier on next steps with galectin-1 for head and neck cancer
-
1:00:44
targeting cancer pathways: understanding immune checkpoints
-
5:58
ctla4 and attenuation of t cell response
-
7:15
our four pillars of cancer immunology research
-
0:37
dr. jacques galipeau: immunotherapy and cancer- introduction to dr. galipea
-
9:02
pd1/ ctla4 : upfront or sequentially?
-
53:11
glyco-checkpoints as therapeutic targets in cancer, autoimmunity & infection by dr. g. rabinovich
-
3:22
should immune checkpoint inhibitors and other therapies be combined concurrently or sequentially?
-
1:01
using bacteria to target tumors
-
23:46
targeting oncogenic drivers for solid tumor cancers with affini-t therapeutics' dr. jak knowles
-
4:15
multikinase inhibitor overall survival advantage
-
1:34
dr. jacques galipeau: immunotherapy and cancer- immune suppression and cancer
-
4:43
impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer
-
9:40
assessing expression of immune checkpoints
-
2:11
dr. weiss on next steps for immunotherapy in head and neck cancer